Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

J Bailey, C; C Morales Villegas, E; Woo, V; Tang, W; Ptaszynska, A; F List, J

doi:10.1111/dme.12624

Public

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Shared by NobleBlocks on Apr 1, 2015 • 12:00 AM UTC

Authors:

C J Bailey

E C Morales Villegas

V Woo

Abstract

AIMS: To assess initial pharmacotherapy of Type 2 diabetes with the sodium-glucose cotransporter-2 inhibitor dapagliflozin. METHODS: This double-blind, placebo-controlled trial, randomly allocated people with Type 2 diabetes aged 18-77 years and inadequate glycaemic control on diet and exercise [HbA...

Discussions